2026-09-24T00:20:08.000Z · 6 days ago Cathie Wood’s ARK Investment buys 143.3K shares of Scribe Therapeutics today
Sep 2, 2026, 4:05 PM EDT · 4 weeks ago Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Sep 1, 2026, 8:00 AM EDT · 4 weeks ago Scribe Therapeutics to Participate in Upcoming Investor Conferences
2026-08-18T17:10:10.000Z · 6 weeks ago Leerink starts Scribe Therapeutics at Outperform on X-editor platform
2026-08-18T09:05:07.000Z · 6 weeks ago Scribe Therapeutics initiated with an Overweight at Wells Fargo
2026-08-18T08:15:11.000Z · 6 weeks ago Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Jul 27, 2026, 4:05 PM EDT · 2 months ago Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
2026-07-27T15:25:46.000Z · 2 months ago Opening Day: Scribe Therapeutics makes strong trading debut BCCQ BSP CCCT CGCF ECR FDMM FWAC
2026-07-24T16:00:48.000Z · 2 months ago Scribe Therapeutics opens at $25, IPO priced at $15 per share
2026-07-24T15:25:24.000Z · 2 months ago Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share
2026-07-24T15:00:12.000Z · 2 months ago Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share
Jul 23, 2026, 9:08 PM EDT · 2 months ago Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Jul 2, 2026, 1:30 PM EDT · 3 months ago Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO